Abstract:
Objective To investigate the prevalence of hyperuricemia (HUA) in people with physical examination and analyze the influence of different levels of serum uric acid (SUA) on glomerular filtration rate.
Methods Clinical materials of 2 753 people with physical examination were collected, and these people were divided into 4 groups according to quartile of SUA level: group Ⅰ (SUA was 246.65 μmol/L and below), group Ⅱ (SUA was greater than 246.65 and up to 309.30 μmol/L), group Ⅲ (SUA was greater than 309.30 and up to 365.55 μmol/L), and group Ⅳ (SUA was greater than 365.55 μmol/L). Pearson correlation analysis was used to explore the associations between the estimated glomerular filtration rate (eGFR) and other biochemical indicators such as SUA. Multivariate Logistics regression analysis was used to study the correlation between different levels of SUA and chronic kidney disease (CKD).
Results The total prevalence of HUA in 2 753 cases was 10.28%, and was 13.73% in men, which was significantly higher than 2.86% in women (P < 0.001). The prevalence of HUA was the highest in men aged 31 to 40 years old, while that was 7.21% in women aged over 70 years old. The eGFR decreased significantly with increase of SUA level (P < 0.001). Pearson correlation analysis showed that the level of SUA was negatively associated with the eGFR (r=-0.186, P < 0.001). Multivariate Logistics regression analysis showed that when confounding factors were not adjusted, the OR values of suffering from CKD in group Ⅱ and group Ⅳ were 0.487 (95%CI, 0.265 to 0.897, P < 0.05) and 2.621 (95%CI, 1.712 to 4.013, P < 0.01) respectively when compared with group Ⅰ; after adjusting for relevant confounding factors, the OR values of suffering from CKD in group Ⅱ and group Ⅳ were 0.622 (95%CI, 0.305 to 1.272, P>0.05) and 3.089 (95%CI, 1.735 to 5.500, P < 0.01) respectively when compared with group Ⅰ.
Conclusion The prevalence of HUA in men with physical examination is higher than that in women. SUA is a risk factor for CKD when its level is greater than 365.55 μmol/L, and the risk of suffering from CKD is high, so it is suggested that initial uric acid lowering therapy should be considered in clinic.